



**DR. PAUL J. DAVIS, M.D.**

Department of Medicine, Albany Medical College, Albany, NY USA; Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY USA; Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan

**BIO:** Dr. Davis served as Chair, Department of Medicine, Albany Medical College from 1990-2000 and is currently Executive Vice President and Chief Scientific Officer of NanoPharmaceuticals, LLC. He obtained his B.A. from Westminster College (MO) and his M.D. from Harvard Medical School. His postgraduate training was at Albert Einstein College of Medicine (NY) and the NIH. He has served on the medical faculties of Johns Hopkins University, the University at Buffalo and Albany Medical College. He has also served as President of the American Thyroid Association, as Governor, New York Chapter, American College of Physicians and on the Board of Directors of the American Board of Internal Medicine. He has co-authored 270 research publications, dealing largely with molecular mechanisms of thyroid hormone action. He and Shaker A. Mousa described the cell surface thyroid hormone receptor on integrin  $\alpha v \beta 3$ . Davis has co-edited four textbooks, two of which deal with regulation of angiogenesis.

**PRESENTATION TITLE:** *The Thyroid Hormone Receptor on the Cancer Cell Plasma Membrane Integrin  $\alpha v \beta 3$  Regulates Cell Proliferation, Anti-Apoptosis, Immune Checkpoint Defense and Angiogenesis*